BIOME AUSTRALIA LIMITED (BIO)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

BIO

BIO - BIOME AUSTRALIA LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Household & Personal Products
Debt/EBITDA: 1.38
Index:

0

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.33

27 Aug
2026

0.050

OPEN

$0.31

17.86%

HIGH

$0.35

1,403,112

LOW

$0.31

TARGET
$0.75 127.3% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGN . ARX . ATH . AVH . BOT . COV . CSL . CUV . DXB . GSS . HXL . IDT . ILA . IMM . IMU . IVX . LGP . MAP . MSB . MVP . MYX . NEU . NUZ . OCC . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
BIO: 1
Title FY25
Actual		 FY26
Actual		 FY27
Forecast		 FY28
Forecast
EPS (cps) xxx 1.6 1.6 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx 100.0% - 1.2% xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 21.3 xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202120222023202420252026
EPS Basic xxxxxxxxxxxxxxx1.6
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx23.9 M
Book Value Per Share xxxxxxxxxxxxxxx4.1
Net Operating Cash Flow xxxxxxxxxxxxxxx1.6 M
Net Profit Margin xxxxxxxxxxxxxxx15.11 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202120222023202420252026
Return on Capital Employed xxxxxxxxxxxxxxx51.34 %
Return on Invested Capital xxxxxxxxxxxxxxx48.39 %
Return on Assets xxxxxxxxxxxxxxx26.07 %
Return on Equity xxxxxxxxxxxxxxx51.34 %
Return on Total Capital xxxxxxxxxxxxxxx17.89 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx1.4 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202120222023202420252026
Short-Term Debt xxxxxxxxxxxxxxx2 M
Long Term Debt xxxxxxxxxxxxxxx1 M
Total Debt xxxxxxxxxxxxxxx3 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx4 M
Price To Book Value xxxxxxxxxxxxxxx6.44

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202120222023202420252026
Capex xxxxxxxxxxxxxxx0.5 M
Capex % of Sales xxxxxxxxxxxxxxx2.05 %
Cost of Goods Sold xxxxxxxxxxxxxxx17 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx5 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx-

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

27/08/2026

1

Buy

$0.75

127.27%

Biome Australia's reported FY26 normalised profit of $1.2m, up from $0.2m in FY25. The result was lower than expected, as opex was higher than expected, growing at 26% after 16% growth last year.

FY27 is the final year of the Vision27 strategic plan to deliver cumulative sales of $75m over three years. Biome needs sales of $33m in FY27 to achieve the target, Bell Potter notes, representing 38% growth after a year of 30%.

The international business is expected to make a much larger contribution after relatively modest growth in FY26. Bell Potter would also expect to see several new products launched.

Buy and 75c target retained.

FORECAST
Bell Potter forecasts a full year FY27 dividend of 0.00 cents and EPS of 1.60 cents.
Bell Potter forecasts a full year FY28 dividend of 0.00 cents and EPS of 2.40 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

0

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Extra Coverage Research History >

BIO STOCK CHART

FNArena News on BIO

1
FNArena Corporate Results Monitor – 27-08-2026

Aug 27 2026 - Australia
2
FNArena Corporate Results Monitor – 24-02-2026

Feb 24 2026 - Australia
3
Rudi’s View: Pre-February Top Picks & Favourites

Jan 15 2026 - Rudi's View
4
FNArena Corporate Results Monitor – 28-08-2025

Aug 28 2025 - Australia
5
Rudi’s View: Best Ideas & Conviction Calls

Feb 20 2025 - Rudi's View

Latest Pharmaceuticals & Biotech/Lifesciences News

1
CSL’s FY26 Suggests The Downtrend Is Done

Aug 19 2026 - Australia
2
Strong Result, Can Telix Continue To Deliver?

Jul 22 2026 - Australia
3
CSL Challenges Pile On, Where’s The Upside?

May 13 2026 - Australia
4
The Biotech ‘Industrialisation’

Apr 20 2026 - Small Caps
5
Telix’ Double-Product Strategy On A Roll

Apr 10 2026 - Australia
6
Focus On Telix’ Guidance Post Annus Horribilis

Jan 22 2026 - Australia
7
Anti-Vaxxers & China Cloud CSL’s Future

Oct 31 2025 - Australia
8
Rudi Interviewed: Diary Of A Successful Investor

Oct 20 2025 - Rudi's View
9
Is CSL Starting Its Price Recovery?

Sep 30 2025 - Technicals
10
Undervalued ASX Gems In Precision Medicine

Sep 23 2025 - Small Caps